Financial toxicity, a treatment-related financial burden, is a major concern among patients with bladder cancer and is common among younger patients, a recent study has shown. Those who endorse financial toxicity face delays in care and have poorer health-related quality of life (HRQOL), suggesting the critical role of treatment costs in medical decision-making.
A recent phase III study has found that office-based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and is safe for surveillance. Blue light cystoscopy in the operating room also improves the detection of carcinoma in situ and exposes lesions that are missed with white light cystoscopy.
Infants delivered via caesarean section may be at increased risk of developing acute lymphoblastic leukaemia, according to a US study. Altered microbiota colonization is a possible explanation for this risk, although clear biological mechanisms have yet to be established.
Hybrid capture-based comprehensive genomic profiling (CGP) may have the capability to detect epidermal growth factor receptor (EGFR) point mutations in non-small cell lung cancer (NSCLC) that were missed by standard-of-care molecular EGFR testing, a recent study found.
False over- and understaging seems to be common with the use of endoscopic ultrasound (EUS) to stage Barrett’s oesophagus (BE) patients with early neoplasia and dysplasia, a recent meta-analysis has shown.
High use of hydrochlorothiazide (HCTZ) appears to significantly increase the risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), suggests a recent study. Use of other diuretic and antihypertensive medications does not appear to be linked to NMSC.
Patients with early-stage breast cancer experience distinct long-term trajectories of cognitive function, a recent Singapore study has shown. Moreover, the risk of cognitive impairment during survivorship appears to be higher in those with self-perceived declines in cognitive function during chemotherapy.
MRI, with or without targeted biopsy, detects more clinically significant prostate cancer and less clinically insignificant prostate cancer than the standard transrectal ultrasonography (TRUS)-guided approach, enabling more than one-quarter of patients to safely avoid a biopsy altogether.
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.